Apotex v. Boehringer-Ingelheim: Nintedanib ANDA Wins Non-Infringement in 291 Days
Apotex filed a declaratory judgment action in Delaware against Boehringer-Ingelheim over two nintedanib capsule formulation patents — US9907756 and US10105323 — covering its generic 100mg and 150mg ANDA products. The parties reached a consent final judgment of non-infringement in under ten months, clearing Apotex’s ANDA No. 219227 for both patents.
Apotex clears nintedanib ANDA via consent non-infringement judgment
On 13 May 2024, Apotex, Inc. filed a declaratory judgment complaint in the Delaware District Court — Case No. 1:24-cv-00577 before Judge Maryellen Noreika — against three Boehringer-Ingelheim entities. Apotex sought declarations that its ANDA No. 219227, covering generic nintedanib 100mg and 150mg capsules, did not infringe US Patent No. 9,907,756 or US Patent No. 10,105,323, both protecting capsule and immediate-release formulations of the indolinone derivative nintedanib, marketed by Boehringer as Ofev.
The case closed on 28 February 2025 — 291 days after filing — when the parties jointly submitted a consent Final Judgment and Order. The court entered final judgment that the manufacture, use, sale, offer for sale, and importation of Apotex’s ANDA products do not and will not infringe any claim of either patent. The judgment expressly operates only with respect to ANDA No. 219227 and the two named patents, with no preclusive effect on any other ANDA, product, or patent.
Resolution in under ten months — before any substantive motion practice appeared on the public docket — suggests the parties reached a licensing or market-access agreement, though the consideration is described only as ‘good cause and valuable consideration’ without public disclosure of specific terms. The each-side-bears-own-costs provision is consistent with a negotiated settlement. What remains unknown is whether Apotex received an authorised launch date, a royalty arrangement, or another form of commercial accommodation from Boehringer.
Filing to Judgment on the merits for Plaintiff in 291 days
291 days — resolved faster than the median Hatch-Waxman DJ action in Delaware
Consent final judgment: what the non-infringement ruling means for both parties
Consent final judgment — merits ruling, not settlement dismissal
Unlike a voluntary dismissal or stipulated dismissal under Rule 41, the parties here sought and obtained a court-entered final judgment on the merits of non-infringement. The court affirmatively found and decreed non-infringement of both the ‘756 and ‘323 patents with respect to ANDA No. 219227. This is a substantive adjudication, giving Apotex a binding, court-entered order it can rely upon to the extent permitted by law.
Merits adjudicationApotex secures ANDA clearance on both formulation patents
Apotex holds a court-entered final judgment confirming its generic nintedanib capsules (100mg and 150mg) do not infringe US9907756 or US10105323. This judgment may be relied upon in connection with ANDA No. 219227, providing regulatory and commercial certainty for a generic nintedanib launch. The scope is limited to Apotex’s specific ANDA and products, but the non-infringement finding is on the merits.
Non-infringement confirmedBoehringer consents but limits precedential reach
Boehringer consented to the non-infringement judgment, strongly suggesting a commercial arrangement underpins the resolution. Critically, the judgment carries no preclusive effect against Boehringer in any proceeding involving any other ANDA, product, or patent. This structural protection means Boehringer retains full ability to enforce US9907756 and US10105323 against other generic filers, limiting the competitive damage of this concession.
No cross-ANDA preclusionGeneric nintedanib market access: what the ruling signals
Nintedanib (Ofev) is a significant IPF and oncology product. A consent non-infringement judgment for one generic filer typically signals a negotiated entry strategy — potentially including a licensed launch date. Other ANDA filers for nintedanib should note that Boehringer’s formulation patents remain fully enforceable against them; this judgment creates no clearing precedent for rival generics. The indolinone capsule formulation space remains a live IP enforcement target.
Negotiated generic entry signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Apotex, Inc. | Company | Canadian generic pharmaceutical company — holder of ANDA No. 219227 for generic nintedanib capsulesSearch in Eureka ↗ |
| Defendant | Boehringer-Ingelheim | Individual | Boehringer-Ingelheim — originator and patent holder for Ofev (nintedanib) indolinone formulationsSearch in Eureka ↗ |
| Co-Defendant | Boehringer Ingelheim Pharma Gmbh & Co., KG | Company | Search in Eureka ↗ |
| Co-Defendant | Boehringer Ingelheim International, GMBH | Company | Search in Eureka ↗ |
| Plaintiff counsel | Aaron M. Johnson | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Plaintiff counsel | John C. Phillips | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan C. Haney | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | Jeremy A. Tigan | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Defendant law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Boehringer-IngelheimSearch in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The final judgment is unusually explicit for a consent order: the court itself found and decreed non-infringement — not merely recorded the parties’ agreement. Paragraph 6 grants Apotex affirmative reliance rights tied to ANDA No. 219227, which may support FDA interactions. Paragraph 7’s strict no-preclusion carve-out reflects Boehringer’s intent to preserve full enforcement rights against all other generic challengers, a formulation that limits the precedential value of this outcome for the broader nintedanib generic market.
US9907756 & US10105323 — nintedanib indolinone capsule formulations
US9907756B2 (application US15/204277) and US10105323B2 (application US15/590487) both protect pharmaceutical dosage forms of nintedanib, an indolinone-class tyrosine kinase inhibitor approved as Ofev for idiopathic pulmonary fibrosis and oncology indications. The patents cover capsule formulations — including immediate-release and suspension-based designs — that likely address bioavailability, stability, or manufacturing characteristics of this small-molecule compound. Both applications were filed in the mid-2010s, placing them well within the Ofev commercial lifecycle.
For Boehringer-Ingelheim, these formulation patents represent a secondary layer of protection beyond any compound patent, extending the commercial exclusivity window for Ofev into the mid-2030s on current term projections. Generic entrants must navigate not only the compound IP but the layered formulation claims. The fact that Boehringer consented to non-infringement for Apotex’s specific ANDA — without conceding claim invalidity — suggests the formulation claims remain strategically viable enforcement tools against other generic developers working with different capsule formulation approaches.
Should your nintedanib ANDA be cleared against US9907756 and US10105323?
Any pharmaceutical company with a pending or planned ANDA for generic nintedanib capsules should treat US9907756 and US10105323 as live enforcement risks. The Apotex consent judgment explicitly provides no clearing effect for any other ANDA filer. R&D and regulatory teams developing nintedanib 100mg or 150mg capsule formulations — whether suspension-based or immediate-release — should conduct independent FTO analysis against the specific claim language of both patents before committing to a formulation strategy.
PatSnap Eureka’s FTO Search Agent can map your formulation parameters against the asserted claims of US9907756 and US10105323, flag relevant prosecution history estoppel, and identify design-around strategies documented in the prior art. Eureka’s claim-chart generation and litigation overlay features let IP counsel assess how Boehringer has historically enforced these patents and which claim elements drove the Apotex resolution, supporting faster and more defensible FTO opinions.
Run a freedom-to-operate analysis on US10105323B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA declaratory judgment cases in Delaware
Cases involving pharmaceutical formulation patent DJ actions for generic capsule products in the Delaware District Court, including other nintedanib and indolinone-related ANDA disputes.
What this case signals for the generic pharmaceutical IP landscape
This consent judgment illustrates how Hatch-Waxman DJ actions can resolve quickly when both parties have aligned commercial incentives.
Consent judgments with no-preclusion clauses protect originator enforcement
Boehringer’s insistence on a no-preclusion clause is a standard but strategically important defensive tool. Any other generic filer challenging US9907756 or US10105323 cannot invoke this judgment. IP teams defending formulation patents in multi-ANDA environments should build this language into every consent order.
Speed of resolution suggests undisclosed commercial terms drove outcome
A 291-day lifecycle ending in a merits consent judgment — with no substantive motion practice — is consistent with a negotiated launch-date or royalty arrangement. For generic entrants, securing a court-entered non-infringement order rather than a bare dismissal provides stronger regulatory footing when interacting with FDA.
Apotex v Boehringer-Ingelheim — key questions answered
The Delaware District Court entered a consent Final Judgment on 28 February 2025 declaring that Apotex’s generic nintedanib 100mg and 150mg capsules under ANDA No. 219227 do not infringe US9907756 or US10105323. The judgment was entered on the merits and may be relied upon by Apotex in connection with that specific ANDA.
No. Paragraph 7 of the Final Judgment explicitly states it has no preclusive effect in any proceeding involving any other ANDA or product. Boehringer retains full enforcement rights against all other generic filers. Other ANDA holders seeking to launch generic nintedanib must independently establish non-infringement or invalidity of US9907756 and US10105323.
Two patents were at issue: US Patent No. 9,907,756 (application US15/204277) covering a capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative, and US Patent No. 10,105,323 (application US15/590487) covering a pharmaceutical dosage form for immediate release of an indolinone derivative. Both cover formulations of nintedanib, marketed as Ofev.
The public record does not specify the precise procedural trigger. Under Hatch-Waxman, a generic filer may bring a DJ action if no infringement suit is filed within 45 days of a Paragraph IV notice, or in other circumstances creating a justiciable controversy. Filing a DJ action allows the generic to control timing and forum rather than waiting for the originator to sue.
An each-side-bears-own-costs provision is consistent with a negotiated resolution rather than a contested litigation outcome. It suggests neither party sought to characterise the other as the losing party for fee purposes, which typically accompanies settlements or commercial agreements that make litigation economics secondary to the underlying business terms — possibly including a licensed launch date or revenue-sharing arrangement whose terms are not publicly disclosed.
PatSnap Eureka searches patents and litigation data to answer instantly.